HOME >> BIOLOGY >> NEWS
Aspirin targets key cell that triggers organ rejection and other immune responses, report University of Pittsburgh researchers in journal article

Animal studies suggest there could be an effective, cheap approach to preventing rejection

PITTSBURGH, June 5 -- University of Pittsburgh researchers have identified a new cellular target for aspirin, shedding light on the mechanisms of the most widely used drug in the world and raising a set of intriguing questions, including whether aspirin could be useful for preventing organ rejection.

In the June 15 issue of the Journal of Immunology, the researchers report for the first time that aspirin has a profound effect on bone-marrow derived dendritic cells -- the powerful immune system cells that are responsible for initiating an immune response -- by preventing their maturation and hence, their ability to signal other cells to attack.

The findings help to explain why aspirin taken in high doses significantly reduces inflammation and provides relief to patients with various autoimmune diseases, including arthritis and rheumatic fever, says lead author Holger Hackstein, M.D., a visiting research fellow at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute, who is working in the lab of Angus Thomson, Ph.D., D.Sc., professor of surgery and molecular genetics and biochemistry and senior author on the paper.

And while the research used a mouse model to look at aspirin's effect on myeloid dendritic cells, the findings point to possible novel therapies for patients with autoimmune diseases as well as approaches that could induce tolerance in organ transplant recipients. The researchers plan a series of animal studies to determine if aspirin can help prevent organ rejection. Specifically, they will be looking to see what role aspirin has in preventing dendritic cells from calling in the troops of T and B lymphocytes that directly attack transplanted organs.

"These findings provide new insight into the immunopharmacology of aspirin. Moreover, exposure to this readily available drug provides a simple, inexpe
'"/>

Contact: Lisa Rossi
rossiL@msx.upmc.edu
412-647-3555
University of Pittsburgh Medical Center
4-Jun-2001


Page: 1 2 3

Related biology news :

1. Aspirin use safe and effective in patients with abnormal red cell counts (or with polycythemia)
2. Aspirin may not be strong enough to prevent clots in some heart patients
3. Aspirin could reduce the risk of deadly infections
4. Aspirin prevents polyps in colon cancer patients
5. Aspirin inhibits ovarian cancer growth, lab study finds
6. Aspirin use may increase pancreatic cancer risk
7. How Super Are The "Super Aspirins"? -- New COX-2 Inhibitors May Elevate Cardiovascular Risk
8. Aspirin Decreases Genetic Mutations Associated With Inherited Colon Cancer
9. Study Shows Aspirin Blocks "Plant Pain"
10. Aspirins Preventive Action In Heart Attacks Tied To Genetics
11. Images of tail of protein needed for cell multiplication suggest anticancer drug targets

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
Cached News: